US Patent 7,838,009: Direct Intracavitary Botulinum Toxin Injection for Obstructed Kidney or Pancreas

US 7,838,009 claims a treatment method for subjects with naturally formed kidney stones or naturally formed pancreatic duct stones by direct injection of an effective amount of botulinum toxin into the obstructed kidney or obstructed pancreas. The claims are narrow by mechanism of delivery (direct injection into the obstructed organ) and narrow by patient condition (naturally formed kidney or pancreatic duct stones). The landscape risk is moderate because the core idea (botulinum toxin for smooth muscle spasm or urinary/pancreatic outflow obstruction) is broadly explored in prior art, but the specific “direct injection into an organ obstructed by a naturally formed stone” framing is more constrained. Enforceability turns on whether prior art already disclosed direct organ injection of botulinum toxin for stone-driven obstruction, and on whether a person of skill would see “naturally formed kidney stone” and “naturally formed pancreatic duct stone” as the relevant indications for direct botulinum toxin delivery.

What exactly does US 7,838,009 claim?

Claim scope and structure

US 7,838,009 contains five method claims:

Claim	Core limitation(s)	What it covers
1	Treat subject with kidney obstructed by a naturally formed kidney stone OR pancreas obstructed by a naturally formed pancreatic duct stone; method comprises direct injection of an effective amount of botulinum toxin solution/suspension into the obstructed kidney/pancreas	Two indication families (urolithiasis and pancreatic duct lithiasis) with one delivery mechanism (direct organ injection of botulinum toxin)
2	Botulinum toxin type A, B, or F	Toxin subtype flexibility
3	Botulinum toxin type A	Narrow subset
4	Subject has naturally formed kidney stone	Narrows from dual-organ to kidney
5	Subject has naturally formed pancreatic duct stone	Narrows from dual-organ to pancreas

Key claim constraints that materially narrow coverage

“Naturally formed” stones: The claims target stones that arise in vivo, not experimentally induced obstructions or inert models.
“Obstructed kidney” / “obstructed pancreas”: The obstruction is anatomical/functional at the organ level, not just a distal passage.
“Direct injection” into the organ: This delivery requirement is the central differentiator versus literature focused on systemic delivery, topical application, or ductal interventions performed via endoscopy without injection.
“Effective amount of a solution or suspension”: The claims assume injectable formulations compatible with toxin delivery.

How strong are the novelty and non-obviousness arguments?

Novelty risk: does prior art already disclose direct injection of botulinum toxin for stone-driven obstruction?

The primary novelty hinge is whether earlier publications and patents disclose:

Botulinum toxin administered by direct injection into the kidney or pancreas, and
The therapeutic rationale tied to obstruction caused by naturally formed stones, not merely spasm, stenosis, or functional dyskinesia.

Across the broader botulinum toxin literature, the most common indications are:

Urology: ureteral spasm, bladder outlet issues, neurogenic dysfunction.
Gastroenterology/pancreatology: sphincter of Oddi relaxation and management of functional obstruction, including pain syndromes related to spasm.

Those uses can create anticipation-like arguments if any reference expressly connects botulinum toxin with stone-associated obstruction and uses direct injection into the obstructed organ rather than treating a downstream functional mechanism.

Non-obviousness risk: “stone obstruction” can be reframed as a smooth muscle/outflow problem

Even if no single reference discloses the exact combination, obviousness can be attacked through the following logic chain:

Botulinum toxin is known to relax smooth muscle and reduce spasm.
Stone obstruction is known to involve pain, spasm, and increased outflow resistance at or near the obstructed segment.
A skilled person could reasonably apply known botulinum toxin relaxation effects to improve clearance or reduce symptoms in stone patients.

That said, US 7,838,009 narrows the proposed solution to direct organ injection and to naturally formed stones in kidney or pancreatic duct. Prior art that only treats functional disorders (or treats sphincter spasm) without direct organ injection weakens anticipation and strengthens non-obviousness.

What claim elements will matter in a validity challenge?

1) “Direct injection … into the obstructed kidney/pancreas”

This is the highest-value feature for both validity and infringement analysis.

For invalidity: the accused prior art must show injection performed into the kidney or pancreas (not systemic dosing, not localized topical application, not injection into a distant structure unless functionally equivalent and explicitly described as such).
For infringement: an accused procedure must match both site (obstructed organ) and delivery mode (injection) and include botulinum toxin as the active agent.

2) “Naturally formed” stones

This matters if prior art used:

animal models with induced obstruction,
surgical or mechanical obstruction models,
phantom or external obstruction.

If a reference uses “stone-like” models but not “naturally formed” stones, it may not map cleanly to the claim text, though courts may still treat the limitation as met by functional equivalence depending on context.

3) “Effective amount of a solution or suspension”

This element is usually less distinguishing because injectable formulations of botulinum toxin are widely known. In practice, this feature rarely saves novelty if the therapeutic act is otherwise disclosed.

4) Toxin type selection (A, B, F) and claim 3 (A only)

Claim 2 broadens to A/B/F, reducing design-around options that swap subtype.
Claim 3 is narrower; if earlier art focuses on toxin type A only, claim 3 becomes more vulnerable on obviousness and anticipation. If earlier art uses types B or F, claim 3 may still face validity risk through substitution arguments.

Infringement: what would likely constitute practice of the method claims?

Direct injection procedures

A procedure most likely to fall within Claim 1 involves:

identifying an obstructed kidney due to a naturally formed kidney stone,
injecting a botulinum toxin solution/suspension directly into the obstructed kidney tissue (or a defined part of it as described by the patent),
or the analogous approach for pancreatic duct stone with injection into the obstructed pancreas.

Design-around opportunities

Potential design-arounds, based on claim language structure:

Change the injection site (if injection is into a different anatomical structure and the method does not inject “into the obstructed kidney/pancreas”).
Use non-injection routes (systemic administration, inhalation, topical, or other delivery).
Treat a different clinical state (functional spasm without a naturally formed stone obstruction).
Avoid using botulinum toxin (substitute another neuromodulator or smooth muscle relaxant).

What does the patent landscape likely look like (and where does it concentrate)?

Where the prior art is dense

Urology botulinum toxin: There is extensive work on botulinum toxin for lower urinary tract dysfunction and ureteral spasm.
Pancreaticobiliary botulinum toxin: There is extensive work on sphincter-related pain and outflow obstruction, often targeting the sphincter of Oddi rather than injecting the pancreas itself.
Endoscopic and image-guided injections: Techniques for delivering botulinum toxin via endoscopic ultrasound (EUS) or imaging-guided injection into pancreatic-related structures are frequently disclosed.

This landscape increases the likelihood that an examiner or challenger will argue obviousness via known spasm reduction and known injection techniques. The decisive question becomes whether stone-associated anatomical obstruction with direct injection into kidney/pancreas is already disclosed.

Where the landscape may be thinner

Explicit stone indications tied to direct organ injection.
Pancreatic duct stone treatments using botulinum toxin injected into pancreatic tissue specifically for clearance or obstruction resolution, rather than for sphincter-mediated symptoms.

Critical read of the claim strategy in US 7,838,009

The patent buys a broad method claim with two indication funnels

Claim 1 blends:

a urology indication (kidney stone obstruction), and
a pancreatic indication (pancreatic duct stone obstruction).

This increases commercial coverage across two markets but also raises validity exposure: challengers can cite whichever prior art is stronger for one organ and use it to attack the broader method concept.

The patent uses a single unifying act: direct injection

If the patent’s novelty rests on direct injection, then enforceability will depend on:

how broadly “direct injection” is interpreted, and
whether prior art injections that are arguably “direct” but delivered to adjacent structures get treated as substitutes.

The patent does not claim device, dosing regimen, or imaging modality

It claims a method act without specifying:

dose ranges,
injection depth or exact anatomical targets,
timing relative to stone diagnosis,
procedural equipment.

That increases infringement potential (because variations may still fall inside “effective amount” and “solution/suspension”), but it also increases obviousness risk because many procedural parameters are left open and likely considered routine to skilled clinicians once the act is conceived.

Risk matrix for investors and competitors

Validity risk by claim layer

Claim	Main risk driver	Practical implication
Claim 1	Prior art mapping to: stone obstruction + botulinum toxin + direct injection into kidney/pancreas	Highest risk exposure; one strong anticipation or obviousness path can invalidate the core claim
Claim 2	Prior art disclosing different toxin types	If A/B/F are all known in relevant contexts, claim 2 collapses into claim 1’s risk
Claim 3 (A only)	Prior art using type A in related organ injection	Narrowing may not rescue validity if type A is the most common toxin in prior art
Claim 4 (kidney only)	Urology stone + botulinum toxin injection prior art	A kidney-focused reference may dominate
Claim 5 (pancreas only)	Pancreatic duct stone + botulinum toxin injection prior art	Pancreas-focused references may dominate; if none exist with “naturally formed pancreatic duct stone” + direct pancreas injection, this claim may be comparatively stronger

Enforceability risk

Because Claim 1 is broad in act and does not specify technique details, defendants can attack validity broadly and also argue non-infringement by:

changing injection targets,
altering indications (functional obstruction vs stone),
or shifting from direct organ injection to another delivery site or approach.

What to watch in prosecution history and litigation (high value, high signal)

A patent landscape review for US 7,838,009 typically hinges on:

Whether the patent office allowed the claims over references that disclosed botulinum toxin for spasm/outflow issues,
Whether the patent distinguished stone obstruction specifically,
Whether claim construction in any related disputes treated “direct injection” narrowly (into organ tissue) versus broadly (into adjacent/connected structures).

Without those records, the most reliable way to test the patent is via claim-element mapping against known botulinum injection modalities for urology and pancreaticobiliary indications. The most likely outcome in many challenges is that the strongest prior art for each organ will be used to attack Claim 1’s conceptual breadth, then depend on whether the “direct injection into obstructed organ due to naturally formed stones” limitation remains distinctive.

Key Takeaways

US 7,838,009 claims a method: treating kidney stone obstruction or pancreatic duct stone obstruction by direct injection of botulinum toxin into the obstructed kidney or obstructed pancreas.
The patent’s enforceability depends on the site and delivery mode: “direct injection into the obstructed organ” plus “naturally formed” stone-driven obstruction.
The landscape is likely dense in botulinum toxin for spasm/outflow problems, but validity hinges on whether prior art also discloses the stone indication combined with direct organ injection.
Claims 4 and 5 narrow to single-organ indications and may have different survivability depending on which organ has stronger stone-and-injection prior art.

FAQs

1) What is the central inventive act in US 7,838,009?
Direct injection of an effective amount of botulinum toxin solution or suspension into the obstructed kidney or obstructed pancreas in patients with naturally formed kidney or pancreatic duct stones.

2) Does the patent cover both kidney stones and pancreatic duct stones?
Yes. Claim 1 covers either an obstructed kidney due to a naturally formed kidney stone or an obstructed pancreas due to a naturally formed pancreatic duct stone. Claims 4 and 5 narrow each indication.

3) Are multiple botulinum toxin types covered?
Claim 2 covers type A, type B, and type F; claim 3 narrows to type A.

4) What is the most litigated claim limitation?
The likely battleground is whether prior art shows direct injection into the obstructed kidney/pancreas for stone-based obstruction, versus treating spasm or functional outflow problems through different delivery targets.

5) Can competitors design around by changing toxin type?
They may avoid toxin-subtype matching if they use a toxin not covered, but if the act and indication match, the main design-around is more likely to involve changing route or injection site or avoiding the stone-obstructed clinical framing.

References

[1] United States Patent 7,838,009.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	December 08, 2000	7,838,009	2025-07-06
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	April 29, 2009	7,838,009	2025-07-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 7,838,009

Summary for Patent: 7,838,009